Moxifloxacin

Drug Profile

Moxifloxacin

Alternative Names: Actira; Avalox; Avelox; Avelox IV; Avelox Oral; BAY 128039; Izilox; Megaxin; Moxibay; Moxifloxacine; Octegra; Proflox

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Plague; Respiratory tract infections; Skin and soft tissue infections
  • Phase III Tuberculosis

Most Recent Events

  • 26 Jul 2016 The US FDA approved label for moxifloxacin carries a boxed warning
  • 02 Nov 2015 Global Alliance for TB Drug Development suspends recruitment in a phase III trial for Tuberculosis (Combination therapy) in multiple countries in Africa, Asia, Eastern Europe and Latin America (NCT02342886)
  • 02 Jun 2015 Moxifloxacin is still in phase III development for Tuberculosis (Combination therapy) in China, India, Kenya, Malaysia, Mexico, South Africa, Tanzania, Thailand and Zambia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top